Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination

NCT03455283 · clinicaltrials.gov ↗

COMPLETED

Status

2118

Enrollment

INDUSTRY

Sponsor class

Conditions

Magnetic Resonance Imaging (MRI)

Interventions

DRUG: Clariscan
OTHER: Gadolinium-Based Contrast Agents

Sponsor

GE Healthcare